Neumora Therapeutics, Inc.
Clinical trials sponsored by Neumora Therapeutics, Inc., explained in plain language.
Biotech developing brain disease therapies.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
New depression pill shows promise in Late-Stage trial
Symptom relief CompletedThis study tests an experimental oral medication, NMRA-335140, against a placebo in 332 adults with major depressive disorder. Over 6 weeks, researchers measure changes in depression symptoms using standard rating scales. The goal is to see if the drug can safely reduce depressio…
Phase 3 • Sponsor: Neumora Therapeutics, Inc. • Aim: Symptom relief
Last updated Jul 08, 2026 00:00 UTC
-
New depression pill shows promise in Late-Stage trial
Symptom relief CompletedThis study tests an experimental oral medication, NMRA-335140, against a placebo in 332 adults with major depressive disorder. The goal is to see if the drug reduces depression symptoms over 6 weeks. Participants are randomly assigned to receive either the drug or a placebo, and …
Phase 3 • Sponsor: Neumora Therapeutics, Inc. • Aim: Symptom relief
Last updated Jul 08, 2026 00:00 UTC
-
New drug aims to calm agitation in Alzheimer's patients
Symptom relief CompletedThis early-stage study tested an experimental drug, NMRA-323511, in healthy older adults and people with Alzheimer's disease who experience agitation. The goal was to see if the drug is safe and can reduce agitated behaviors like pacing or yelling. The study involved 87 participa…
Phase 1 • Sponsor: Neumora Therapeutics, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 12:36 UTC
-
New pill hopes to lift bipolar II depression
Symptom relief CompletedThis study tested an oral drug called NMRA-335140 (navacaprant) against a placebo in 18 adults with bipolar II disorder who were currently experiencing a major depressive episode. Over 6 weeks, researchers measured changes in depression symptoms using a standard rating scale. The…
Phase 2 • Sponsor: Neumora Therapeutics, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 12:01 UTC
-
New depression drug shows promise in large trial
Symptom relief CompletedThis study tested an experimental oral drug, NMRA-335140, against a placebo in 383 adults with major depressive disorder. Participants took the drug or placebo daily for 6 weeks, and researchers measured changes in depression symptoms using a standard rating scale. The goal was t…
Phase 3 • Sponsor: Neumora Therapeutics, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 08:00 UTC